Bone Cancer - Pipeline Review, Q2 2011

Global Markets Direct, May 2011, Pages: 157

Bone Cancer - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Bone Cancer - Pipeline Review, Q2 2011', provides an overview of the Bone Cancer therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. 'Bone Cancer - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Cancer.
- A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Bone Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bone Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Bone Cancer
Bone Cancer Therapeutics under Development by Companies
Bone Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Bone Cancer Therapeutics - Products under Development by Companies
Bone Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Bone Cancer Therapeutics Development
F. Hoffmann-La Roche Ltd.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
Gilead Sciences, Inc.
Merck & Co., Inc.
Infinity Pharmaceuticals, Inc.
ZIOPHARM Oncology, Inc.
Oncolytics Biotech Inc.
Simcere Pharmaceutical Group
Onyvax Ltd.
ViroStatics, srl
Hawthorn Pharmaceuticals, Inc.
PharmaMar, S.A.
Eleison Pharmaceuticals, Inc.
Epeius Biotechnologies Corporation
Bone Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Xgeva - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD0530 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
IPI-926 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin Lipid Complex - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Reolysin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRO95780 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Onyvax-105 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCH 717454 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zalypsis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Imatinib mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bivastin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PLG201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BMTP-11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rexin-G - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Liposomal Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiotepa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VS1-011 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Velcade - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Liposomal Vincristine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Alimta - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bevacizumab + Cisplatin + Doxorubicin + Methotrexate + Ifosfamide + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MDX-010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Proline Rich PolyPeptide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Genetically modified T cells - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Doxorubicin hydrochloride + Methotrexate + Pamidronate disodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Trimetrexate + Leucovorin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zometa - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cisplatin + Doxorubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cyclophosphamide + Doxorubicin hydrochloride + Etoposide + Ifosfamide + Vincristine sulfate + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trabectedin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trimetrexate + Leucovorin + Ifosfamide + Doxorubicin + Cisplatin + Filgrastim + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCH 717454 + Temozolomide + Irinotecan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCH 717454 + Vincristine + Doxorubicin + Cyclophosphamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SCH 717454 + Ifosfamide + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Interferon Alpha + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AP23675 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoledronic Acid + Adriamycin + Cisplatinum + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoledronic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vincristine + Doxorubicin + Ifosfamide + Cyclophosfamide + Etoposide + Busulfan + Melfalan + Peripheral Stem Cells Transplantation - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Adrimycin + Cisplatin + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Adrimycin + Cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoledronic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AYRPVSRNI + IFA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AYRPVSRNI + IFA + Interferon Alpha - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Celecoxib + Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Ifosfamide + Vinblastine + Vincristine Sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
High Dose Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Ifosfamide + Epirubicin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Temsirolimus + Valproic Acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Cisplatin + Dexrazoxane + Doxorubicin + Leucovorin + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Trimetrexate + Leucovorin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Doxorubicin + Etoposide + Ifosfamide + Vincristine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
OncoLAR + Tamoxifen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Pazopanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ifosfamide + sorafenib tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oxaliplatin + Gemcitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Sorafenib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Busulfan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Doxorubicin + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
dactinomycin + carboplatin + cyclophosphamide + epirubicin hydrochloride + etoposide + ifosfamide + vincristine sulfate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Gemcitabine + Filgrastim/Pegfilgrastim - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RAD001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Yondelis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GM-CSF - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Treosulfan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zoledronic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Afinitor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
haw mAb11 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Zymafos + Etoposide + Carboplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB0023 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Endostar + Methotrexate + Cisplatin + Pirarubicin + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexrazoxane + Doxorubicin + Cisplatin + Methotrexate + Ifosfamide + Etoposide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexrazoxane + Doxorubicin + Cisplatin + Methotrexate + Ifosfamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiotepa + Melphalan + Allogeneic Hematopoietic Stem Cell Transplantion - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bone Cancer Therapeutics – Drug Profile Updates
Bone Cancer Therapeutics - Discontinued Products
Bone Cancer - Featured News
Apr 03, 2011: Infinity Reports New Preclinical Data For IPI-926 At AACR Supporting Development In Chondrosarcoma
Mar 23, 2011: Infinity To Present New Preclinical Data On IPI-926 At Upcoming AACR Meeting
Mar 03, 2011: Infinity Initiates Phase II Trial Of IPI-926 In Patients With Chondrosarcoma
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014
May 12, 2009: Oncolytics Biotech Inc. Completes Patient Enrolment In U.S. Phase 2 Sarcoma Study For The Trial REO 014
Jul 11, 2007: Amgen and Daiichi Sankyo Announce Agreement For Denosumab In Japan
Apr 19, 2005: Onyvax-105 Cancer Vaccine Shows Encouraging Clinical Results In Osteosarcoma Patients After Intensive Chemotherapy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bone Cancer, Q2 2011
Products under Development for Bone Cancer – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
F. Hoffmann-La Roche Ltd., 2011
Amgen Inc., 2011
AstraZeneca PLC, 2011
Eli Lilly and Company, 2011
Gilead Sciences, Inc., 2011
Merck & Co., Inc., 2011
Infinity Pharmaceuticals, Inc., 2011
ZIOPHARM Oncology, Inc., 2011
Oncolytics Biotech Inc., 2011
Simcere Pharmaceutical Group, 2011
Onyvax Ltd., 2011
ViroStatics, srl, 2011
Hawthorn Pharmaceuticals, Inc., 2011
PharmaMar, S.A., 2011
Eleison Pharmaceuticals, Inc., 2011
Epeius Biotechnologies Corporation, 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Bone Cancer Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Bone Cancer, Q2 2011
Products under Development for Bone Cancer – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Discovery and Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Customers who bought this item also bought

• Neurofibromatoses - Pipeline Review, H2 2012
• Lip Cancer - Pipeline Review, H2 2012
• Neutropenia - Pipeline Review, H2 2012
• Other Hematological Disorders - Pipeline Review, H2 2012
• Bladder Cancer - Pipeline Review, H2 2012
• Oral Cancer - Pipeline Review, H2 2012
• Nausea - Pipeline Review, H2 2012
• Thrombocytopenia - Pipeline Review, H2 2012
• Primitive Neuroectodermal Tumor (PNET) - Pipeline Review, H2 2012
• Non-Hodgkin Lymphoma - Pipeline Review, Q4 2010